Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?
Expert Rev Cardiovasc Ther
; 12(5): 533-6, 2014 May.
Article
em En
| MEDLINE
| ID: mdl-24725228
ABSTRACT
Cardiovascular complications are frequently observed in diabetic patients and are mostly caused by endothelial dysfunction associated with a decline in biosynthesis of nitric oxide (NO). In response to this concern, a remarkable increase in the interest for development of NO-releasing hybrid drugs has been observed. The NO-donating entity was linked to known drugs with the belief that NO is a vasorelaxant and an inhibitor of platelet aggregation or reduces thrombotic events. Many of these NO-releasing hybrid drugs have shown significant improvement in cardiovascular safety. In this editorial the potential roles of NO-releasing drugs for the treatment of cardiovascular complications in diabetes will be discussed.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Doadores de Óxido Nítrico
/
Complicações do Diabetes
/
Óxido Nítrico
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article